Astra Zeneca's vaccine has been suspended in all regions of Sweden since March 16 following a decision by the Swedish Public Health Agency.
This after reports of suspected side effects such as blood clots and bleeding.
On March 18, the European Medicines Agency (EMA) gave the green light for Astra Zeneca's vaccine after examining reported side effects.
Sweden decided to wait and continue the break.
Analyzing
Johan Carlson, Director General of the Swedish Public Health Agency, said at a press conference that a few days were needed to analyze the situation, review the EMA's conclusions and discuss with the Medical Products Agency.
The Swedish Public Health Agency is now announcing that information on how Sweden will deal with Astra Zeneca's vaccine will arrive no earlier than Thursday.
The Swedish Public Health Agency writes in an email to SVT that the work of reviewing the vaccine has been going on all weekend.
The Medical Products Agency does not participate in the actual decision on whether the vaccinations with Astra Zeneca's vaccine should be resumed.
However, the Medical Products Agency, together with the European Medicines Agency, EMA, continues to monitor suspected side effects.